banner
 
bar

program

bar
 
 

AtrialFibrillationWRAP:

Focus on Rhythm Control and Optimizing
Outcome Domains in Patients with AF

MedicineWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period February 28, 2011 through February 28, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

Two hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of and strategies for rhythm control in patients with atrial fibrillation.

Release Date:

February 28, 2011

Expiration Date:

February 28, 2013

Intended Audience:

Electrophysiologists, AF specialists, general cardiologists, cardiology program directors, interventional cardiologists, thrombosis specialists,
hospitalists, hospital-based CV pharmacists, and related disciplines.

Registration:

Enrollment for this MedicineWRAP is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoSupported by an independent educational grant
from sanofi-aventis.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Gerald V. Naccarelli, M.D.
Bernard Trabin Chair in Cardiology
Professor of Medicine
Chief, Division of Cardiology
Penn State Heart and Vascular Institute
Hershey, Pennsylvania

Advisor or consultant: Otsuka Pharmaceutical Co. Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Pfizer Inc.; AstraZeneca Pharmaceuticals LP; Paracor; Transoma; Medtronic, Inc.; sanofi-aventis; CV Therapeutics; Cardiome Pharma Corp.; Novartis Pharmaceuticals Corporation; Wyeth Pharmaceuticals Inc.; Xention; Astellas Pharma, Inc.; GlaxoSmithKline; Biocritique.

Research Support: GlaxoSmithKline; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Medtronic, Inc.; sanofi-aventis.

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Participants in this CME-certified MedicineWRAP will be able to:

  • Optimize rhythm control for patients with new onset AF based on risk stratification strategies that consider symptom severity according to the EHRA categories, and based on likelihood of achieving definitive and permanent rhythm conversion to SR according to their clinical profiles, etiology of AF, presence and degree of HF, EF, symptoms status, and other co-existing factors;

  • Select AF patients, based on risk stratification criteria and clinical history, in order to determine which patients subsets with AF are better candidates for (ventricular) rate control and thromboembolic prophylaxis, and which are ideal candidates for attempts to achieve and maintain pharmacologic conversion to and maintenance of SR;

  • Manage patients with new onset AF, focusing on which individual patients and subgroups would be most likely to respond to and benefit from rhythm control as the primary strategy for reducing complications of AF;

  • Apply the multiplicity of approaches required to optimize clinical outcomes and domains in AF, including prevention of thromboembolism, symptom relief based on EHRA and Canadian symptom scales, correction of rhythm disturbance and maintenance of SR;

  • Understand how the initial strategy in AF patients may differ from long-term therapeutic goals, that is, patients with symptomatic AF lasting many weeks, initial therapy may be anticoagulation and rate control, while the long-term goal may be to restore sinus rhythm;

  • Manage patients in whom rate control offers inadequate symptomatic relief, and in whom restoration of sinus rhythm becomes a clear long-term goal; and more skilled at achieving this clinical targets based on evidence and guidelines;

  • Better educated about and more skilled at recognizing and interpreting predictive factors that can help clinicians, depending on their patient's clinical course, determine which patients are likely to respond to maintenance of NSR with pharmacologic therapy; and to recognize how to respond, pharmacotherapeutically, to the window of opportunity for converting and/or maintaining sinus rhythm, which exists early in the course of management of a patient with AF.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved

 
6

 

Key Program Topics Include:

AAD
ablation
ACC
ACC/AHA
ACCF/AHA/HRS
ACTIVE
ACTIVE W
AF
AFFIRM
AHA           
Amiodarone
ANDROMEDA
Antiarrhythmic
antiarrhythmic drugs
anticoagulant
Anticoagulants
Anticoagulation
Antiplatelet
Antithrombotic
Apixaban
ARISTOTLE


Aspirin
ATHENA
Atrial fibrillation
atrial function
AVERROES
CABANA
Canadian guidelines
cardioversion
CASTLE-AF
Catheter ablation
CHA2DS2-VASc
CHADS2
Clopidogrel
CYP2C9
dabigatran
Dabigatran
Dronedarone
Edoxaban
ENGAGE
ENGAGE AF-TIMI 48
ESC

Flecainide
GISSI-AF
Guidelines
heart failure
Heart Rhythm Society
HRS
INR
Investigational Anticoagulant Targets
Maze operation
Oral Factor Xa Inhibitors
PALLAS
proarrhythmia
PROSPER
PROTECT-AF
RACE
RE-LY
RE-LY Trial
Rhythm
rhythm
rhythm control

Rivaroxaban
ROCKET
ROCKET AF
sinus
sinus rhythm
Sotalol
SPAF
SPORTIF
Stroke
Study Primary Endpoint and Results
systemic emboli
Thromboembolism
Thrombosis
vitamin K
VKORC1
Warfarin
WATCHMAN
Ximelagatran